
    
      To evaluate the effect of multiple subcutaneous (SC) doses of benralizumab (MEDI 563) on the
      rate of moderate-to-severe annualized incidence rate of moderate or severe acute
      exacerbations of chronic obstructive pulmonary disease (AECOPD) in adult subjects with
      moderate-to-severe COPD who exhibit eosinophilia (greater than or equal to [>=] 3.0 percent
      [%] sputum eosinophilia in the previous 12 months or at Screening) in sputum compared to
      placebo.
    
  